Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

Example vaccine vial in clinic © John Cairns
  • Primary analysis, part of pre-specified trial protocol, follows interim analysis on Monday 22 March
  • Data are consistent with interim analysis, and will form submission by AstraZeneca to US FDA
  • Vaccine 76% effective against symptomatic COVID-19, and 100% effective against severe or critical disease and hospitalisation

This primary efficacy analysis included the accrual of 190 symptomatic cases of COVID-19 from the 32,449 trial participants, an additional 49 cases to the previously announced interim analysis.

In addition, results were comparable across age groups, with vaccine efficacy of 85% in adults 65 years and older. A key secondary endpoint, preventing severe or critical disease and hospitalisation, demonstrated 100% efficacy.

Read the full story on the University of Oxford website.

Similar stories

Ethics in Mental Health Digital Innovations for Young People in Africa: Digital Campaign

This campaign was led by a team of 29 Early Career Researchers (ECRs) and a Young People's Advisory Group (YPAG) across five African countries. The young people wanted to share contextual and accessible information on digital mental health and ethical issues that are important to them.

The Duchess of Cornwall opens the new Marcela Botnar wing

A new building at the University of Oxford's Botnar Institute for Musculoskeletal Sciences has been opened by The Duchess of Cornwall.

Cancer Research UK to invest £11 million into cancer science in Oxford

A £11 million Cancer Research UK investment has been awarded to the University of Oxford and Oxford-based NHS to catalyse the translation of its world-leading cancer research for patient benefit.

Review highlights risk factors associated with violence in schizophrenia

Researchers at Oxford University’s Department of Psychiatry have found that people with schizophrenia and related disorders are at higher-than-average risk of perpetrating violence, but that the overall risk remains low (less than 1 in 20 in women, and less than 1 in 4 for men over a 35-year period for violent arrests and crimes).

An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections

First comprehensive analysis of global impact of antimicrobial resistance (AMR) estimates resistance itself caused 1.27 million deaths in 2019 - more deaths than HIV/AIDS or malaria - and that antimicrobial-resistant infections played a role in 4.95 million deaths.

Attention and memory deficits persist for months after recovery from mild Covid

Researchers from Oxford’s Department of Experimental Psychology and Nuffield Department of Clinical Neurosciences have shown that people who have had Covid but don’t complain of long Covid symptoms in daily life nevertheless can show degraded attention and memory for up to 6-9 months.